- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02298387
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
August 10, 2020 updated by: OncoMed Pharmaceuticals, Inc.
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors.
Study includes a dose escalation phase and expansion phase.
Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors.
Study includes a dose escalation phase and expansion phase.
Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Study Type
Interventional
Enrollment (Actual)
71
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Oncology Research Associates, PLLC d/b/a Pinnacle Oncology Hematology
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Stephenson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must have a histologically confirmed malignancy that is metastatic or unresectable for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit or they must be ineligible to receive such therapy and/or have declined all such therapy. In addition, subjects must have a tumor that is at least 1 cm in a single dimension and is radiographically apparent on CT or MRI.
- FFPE tumor tissue either fresh core needle biopsied or archived (two FFPE cores preferred whenever possible) is required for participation in the study. If fresh tissue is obtained, the core biopsy must be done at least ≥7 days prior to Day 0.
- Subjects must have received their last chemotherapy, non-anti-VEGF biologic, or investigational therapy at least 4 weeks prior to enrollment, 6 weeks if the last regimen included BCNU or mitomycin C, and 8 weeks if the last regimen was an anti-VEGF therapy
- Age >21 years
- ECOG performance status <2
- Life expectancy of more than 3 months
Subjects must have adequate organ and marrow function as defined below:
- Absolute neutrophil count >1000/mL (without a colony stimulating factor within the last 2 weeks)
- Hemoglobin >10.5 g/dL (without erythropoietin or blood transfusion within the last 2 weeks)
- Platelets >100,000/mL (without platelet transfusion within the last 2 weeks)
- Total bilirubin <1.5 X institutional upper limit of normal (ULN)
- AST (SGOT) and ALT (SGPT) <2 X institutional ULN (for subjects with hepatic metastases <5 X institutional ULN)
- INR and PTT within 1.5 X institutional ULN
- Proteinuria < trace
- Creatinine <1.5 X institutional ULN OR
- Creatinine clearance >60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
- Women of childbearing potential must have had a prior hysterectomy or have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug. Men must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and from study entry through at least 6 months after discontinuation of study drug. Should a woman enrolled in the study or a female partner of a man enrolled in the study become pregnant or suspect she is pregnant while participating in this study or within 6 months after discontinuation of study, she should inform the Investigator immediately.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Subjects receiving any other investigational agents
- Subjects who have received an anti-DLL4 antibody, or an anti-DLL4/VEGF bispecific antibody Subjects who have received prior anti-VEGF therapy are eligible, unless they have residual serious adverse events related to their anti-VEGF therapy.
- Subjects with a history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess; clinical signs or symptoms of GI obstruction and/or requirement for parenteral hydration or nutrition. In addition, subjects with other known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease.
- Subjects with brain metastases (subjects must have a CT scan or MRI of the head within 28 days prior to enrollment to rule out brain metastases), uncontrolled seizure disorder, or active neurologic disease
- History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
- Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women or nursing women
- Subjects with known HIV infection
- Known bleeding disorder or coagulopathy
- Subjects receiving heparin, warfarin, or other similar anticoagulants, except for subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.
- Subjects with ascites or pleural effusion requiring drainage within the last 28 days.
- Subjects with a blood pressure of >140/90 mmHg.
- Subjects with squamous cell carcinoma of the lung
- Subjects having undergone a major surgery within the last 6 weeks
- New York Heart Association Classification II, III, or IV (see APPENDIX D)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OMP-305B83
The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
|
intravenous (in the vein) infusions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limiting toxicities (DLTs)
Time Frame: Subjects will be assessed for DLTs from Days 0-21. Adverse events will be reported through 30 days after discontinuation of treatment
|
Number of subjects with a DLT
|
Subjects will be assessed for DLTs from Days 0-21. Adverse events will be reported through 30 days after discontinuation of treatment
|
Incidence of adverse events
Time Frame: Up to 2 years
|
Number of subjects with adverse events
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) - AUC, Clearance, volume of distribution, apparent half-life
Time Frame: PK analyses at various time points following the 1st and 3rd doses, pre-dose at Day 84 and every 9 weeks while on study, at treatment term, every 6 weeks for 12 weeks post termination
|
Area under the plasma concentration-time curve, measurement of renal clearance from the body, volume of distribution, apparent half life of antibody
|
PK analyses at various time points following the 1st and 3rd doses, pre-dose at Day 84 and every 9 weeks while on study, at treatment term, every 6 weeks for 12 weeks post termination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Smith, MD,FACP, University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 22, 2014
Primary Completion (Actual)
May 23, 2017
Study Completion (Actual)
September 8, 2017
Study Registration Dates
First Submitted
November 10, 2014
First Submitted That Met QC Criteria
November 19, 2014
First Posted (Estimate)
November 24, 2014
Study Record Updates
Last Update Posted (Actual)
August 11, 2020
Last Update Submitted That Met QC Criteria
August 10, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B83-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor Malignancies
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
New Mexico Cancer Care AllianceCompletedAdvanced Solid Tumor MalignanciesUnited States
-
Georgetown UniversityPfizerUnknownAdvanced Solid Tumor MalignanciesUnited States
-
Novita Pharmaceuticals, Inc.RecruitingAdvanced or Metastatic Solid Tumor MalignanciesUnited States
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAdvanced Or Metastatic Solid Tumor MalignanciesChina
-
GigaGen, Inc.National Cancer Institute (NCI)Not yet recruitingAdvanced or Metastatic Solid Tumor MalignanciesUnited States
-
Astellas Pharma IncCompletedLocally Advanced (Unresectable) or Metastatic Solid Tumor MalignanciesJapan
-
Novartis PharmaceuticalsRecruitingContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesSpain, United States, Taiwan, Singapore, France
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnMetastatic Solid Malignancies | Locally Advanced Solid MalignanciesCanada
Clinical Trials on OMP-305B83
-
OncoMed Pharmaceuticals, Inc.TerminatedMetastatic Colorectal CancerUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Solid TumorsUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedCancer Ovaries | Cancer Peritoneal | Cancer, Fallopian TubeUnited States
-
OncoMed Pharmaceuticals, Inc.Completed
-
OncoMed Pharmaceuticals, Inc.Completed
-
OncoMed Pharmaceuticals, Inc.CompletedSolid TumorsUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
OncoMed Pharmaceuticals, Inc.Novotech (Australia) Pty LimitedCompletedColorectal CancerAustralia, New Zealand
-
OncoMed Pharmaceuticals, Inc.BayerCompleted
-
OncoMed Pharmaceuticals, Inc.TerminatedMetastatic Cancer | Locally Advanced Malignant NeoplasmUnited States